Air Products and Chemicals, Inc. (APD) Sees Large Drop in Short Interest

DAN JONES | February 17, 2017

article image
Air Products and Chemicals, Inc. (NYSE:APD) saw a large decline in short interest in January. As of January 31st, there was short interest totalling 3,003,129 shares, a decline of 37.1% from the January 13th total of 4,777,430 shares. Based on an average daily volume of 2,020,303 shares, the short-interest ratio is presently 1.5 days. Approximately 1.4% of the shares of the stock are short sold. Air Products and Chemicals (NYSE:APD) opened at 141.87 on Friday. Air Products and Chemicals has a 52-week low of $116.91 and a 52-week high of $150.45. The company has a market cap of $30.87 billion, a P/E ratio of 54.63 and a beta of 1.26. The stock’s 50 day moving average price is $143.23 and its 200 day moving average price is $140.73.

Spotlight

Seattle Genetics

Seattle Genetics is dedicated to improving patient outcomes through advanced antibody-drug conjugate technology designed to deliver cell-killing agents directly to tumor cells. The largest global oncology biotechnology company based in the Pacific Northwest, we are focused on developing and commercializing a new generation of targeted, empowered antibody-based therapies that have the potential to change the foundation of treatment for people with cancer. Our industry-leading antibody-drug conjugate (ADC) technology combines the specificity of monoclonal antibodies, innovative linker systems, and the power of potent cell-killing agents to treat cancer. Using our proprietary technology, we are able to optimize each ADC to potentially improve outcomes for patients.

OTHER ARTICLES

Resin and Polymeric Binders for Inks

Article | May 19, 2021

The market size for polymeric and resin binders in the global printing ink marketwas estimated to be over 1,200,000 MT in 2020, with a CAGR of about five percent. A major driver of this growth comes from the packaging industry, due to increases in consumer spending and online shopping, as well as demand for processed and packaged foods and beverages. In addition, increased use of water-based inks is promoting market growth, off-setting environmental and health concerns regarding solvent-based inks in addition to strict environmental protection policies. Water-based inks are projected to overtake solvent-based inks due to environmental regulations, the reduction of volatile organic compounds (VOCs) in the pressroom, and improvements in overall print quality. Ink formulations are complex mixtures, consisting of four basic component classes: pigments, polymeric binder resins, solvents or an aqueous dispersant media, and additives, such as surfactants, waxes, and rheology modifiers that enhance print quality. The purpose of the resin binder is to disperse and carry the ink pigment to the substrate, stabilize the pigment and additives dispersion to prevent settling, and provide print properties such as ink transfer behavior, setting, and drying characteristics. The binder also contributes surface appearance and gloss, strength and flexibility, chemical and solvent resistance, and also rub resistance. Ink binders can be categorized into the following polymer and resin types: acrylics, polyurethanes, polyamides, modified resins, hydrocarbon resins, and modified cellulosics.

Read More

Guyana-Suriname basin: Rise from obscurity to super potential

Article | May 13, 2021

Recent discoveries in the Guyana-Suriname basin attest to estimates of 10+ Bbbl of oil resources and more than 30 Tcf of gas.1 Like many oil & gas successes, this is a story that begins with early exploration success onshore, followed by a long period of exploration disappointment in coastal to shelf regions offshore, eventually culminating in deepwater success.

Read More

Developing pre-rig solutions that are greener, safer and more efficient

Article | May 1, 2021

MAY 2021 ///Vol 242 No. 5 FEATURES Developing pre-rig solutions that are greener, safer and more efficient There is an increased focus in the oil and gas sector to look further afield to opportunities presented in deepwater locations. Because of this, finding cost-efficient solutions and overcoming the associated challenges that arise below 1,000 ft will be vital for the success of new activity. Jostein Aleksandersen, Neodrill There is an increased focus in the oil and gas sector to look further afield to opportunities presented in deepwater locations. Because of this, finding cost-efficient solutions and overcoming the associated challenges that arise below 1,000 ft will be vital for the success of new activity. All those currently—and those considering—operating in deepwater fields will have an awareness of the general challenges that are presented at such depths. From considerations relating to vast increases in pressure, to the potential for increased drilling time and days spent offshore, there are several hurdles that follow when operating in what are often challenging well environments. In addition, suitable solutions also must support the industry drive to reduce emissions by offering a more carbon-efficient approach.

Read More

Transporting biological and chemical materials - what you need to know

Article | February 13, 2020

The landscape of biological and chemical logistics has changed rapidly - as have the regulatory frameworks around it. What has not necessarily kept pace is the end-user understanding of the nature of these logistical processes, their opportunities and their constraints. Twenty years ago, the transmission of biological and chemical materials was limited to a small range of organisations: usually national and international research companies, hospitals, major university departments, police and military departments with forensic responsibilities.

Read More

Spotlight

Seattle Genetics

Seattle Genetics is dedicated to improving patient outcomes through advanced antibody-drug conjugate technology designed to deliver cell-killing agents directly to tumor cells. The largest global oncology biotechnology company based in the Pacific Northwest, we are focused on developing and commercializing a new generation of targeted, empowered antibody-based therapies that have the potential to change the foundation of treatment for people with cancer. Our industry-leading antibody-drug conjugate (ADC) technology combines the specificity of monoclonal antibodies, innovative linker systems, and the power of potent cell-killing agents to treat cancer. Using our proprietary technology, we are able to optimize each ADC to potentially improve outcomes for patients.

Events